Management of Amlapitta(Gastro-oesophageal reflux disease) in Ayurveda

An open labeled clinico-comparative study of Abhayadi Avaleha with or without Sadyovaman, Deepana-Pachana, Rasayana in the management of Urdhvaga Amlapitta

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040677

Enrollment

Registered

2022-02-28

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K219- Gastro-esophageal reflux disease without esophagitis Health Condition 2: K219- Gastro-esophageal reflux disease without esophagitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having classical signs and symptoms of Urdhvaga Amlapitta 2. Age group: 18 – 60 years 3. Chronicity of Urdhvaga Amlapitta less than 5 years 4. Patients willing to participate in the trial

Exclusion criteria

Exclusion criteria: 1. Age below 18 years and above 60 years 2. Pregnant and lactating women 3. Patients having complications like core-pulmonale, pulmonary TB, emphysema, pneumonia, cystic fibrosis, malignancy, severe anaemia, renal failure, congestive cardiac failure. 4. Patients suffering from malignant and accelerated hypertension, stenosis, coronary artery disease, uncontrolled diabetes.

Design outcomes

Primary

Measure	Time frame
Trial drug will break the pathogenesis of Urdhavaga AmlapittaTimepoint: the outcome will be assesed on weekly basis for 8 weeks and follow up for 4 weeks	—

Secondary

Measure	Time frame
The drug will improve the quality of life and thus will act as disease modifying agent for Urdhvaga AmlapittaTimepoint: 60 days	—

Countries

India

Contacts

Public ContactDr Mandip Goyal

Department of Kayachikitsa 4th floor ITRA Jamnagar

mandipgoyal22@gmail.com9427572306

Outcome results